Exploring Psychotropic Medication Use in Hospitalized Children With Autism Spectrum Disorder in China: The Role of Intellectual Disability.
In a Chinese hospital, almost every autistic child got psychiatric drugs, and those with ID were steered toward stronger antipsychotics and polypharmacy instead of milder options.
01Research in Context
What this study did
Doctors in China looked back at 269 kids with autism who stayed in the hospital. They wanted to know how many got psychiatric drugs and if having an intellectual disability changed the choice of drug.
The team read each chart and counted what meds were ordered. They split the kids into two groups: ASD only and ASD plus ID.
What they found
Almost every child, 97 %, left the hospital on at least one psychotropic drug. Kids with ASD plus ID were given antipsychotics and two or more drugs at once far more often. The same kids were given antidepressants and ADHD meds less often.
In plain numbers, ID status flipped the script on prescribing.
How this fits with other research
Smith et al. (2010) saw the same flip in a big U.S. registry, but only 35 % of kids there used meds. The lower rate looks like a contradiction, yet the U.S. sample mixed clinic and community kids while the China study looked only at inpatients. Sicker kids enter hospitals, so higher drug use makes sense.
Congiu et al. (2010) and Hilton et al. (2010) warn that more drug classes raise side-effect risk in people with ID. Wenqing’s group now shows children with ASD plus ID already receive this riskier polypharmacy, backing the warning with fresh numbers.
Hudson et al. (2012) found only a handful of psychotropics have solid RCT proof for ASD targets. The new chart review reveals doctors still prescribe widely off-label, especially when ID is present.
Why it matters
If you work with autistic clients who also have ID, double-check each med at intake. Ask why an antipsychotic was started and if behavior plans were tried first. Track side effects with a simple scale like the MEDS. Your notes can help the team decide if a drug is still needed or if skills training can replace it.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Pull the med list for each ASD-plus-ID client and flag any antipsychotic started without a prior behavior-intervention trial.
02At a glance
03Original abstract
Children and adolescents with autism spectrum disorder (ASD) frequently present with mental health comorbidities and behavioral crises, necessitating inpatient care. However, evidence-based guidelines for psychotropic medication use in specialized inpatient settings remain limited, particularly in non-Western contexts. This study examined the clinical characteristics and prescribing patterns among 269 hospitalized ASD patients (2012-2023), with a focus on how intellectual disability (ID) influences medication decisions. A retrospective analysis was conducted using electronic medical records to assess mental disorders, behavioral challenges, and psychotropic medication use at discharge. Logistic regression analyses was performed to examine factors associated with medication prescribing patterns, including the impact of ID status. Psychotropic medication use was highly prevalent (96.7%), with antipsychotics (89.96%) being the most frequently prescribed class, followed by anxiolytics (35.32%) and antidepressants (33.09%). ID was significantly associated with distinct prescribing patterns: patients with ID had 63% lower odds of antidepressant use (aOR = 0.37, p = 0.001) and 80% lower odds of ADHD medication use (aOR = 0.20, p = 0.009), while being more likely to receive antipsychotics (aOR = 2.74, p = 0.049) and experience polypharmacy (aOR = 1.89, p = 0.028). Additionally, disruptive behaviors and age were key predictors of antipsychotic use, whereas suicidal thoughts/attempts or SIBs independently predicted antidepressant prescribing. These findings suggest that ID status plays a critical role in shaping psychotropic prescribing practices beyond symptom severity alone, potentially reflecting diagnostic overshadowing and safety concerns. Future research should focus on developing tailored clinical assessment tools and treatment protocols for ASD populations with and without ID, while enhancing individualized medication monitoring to optimize therapeutic outcomes.
Journal of autism and developmental disorders, 2025 · doi:10.1007/s10803-017-3153-x